News and Media

Anti-doping news

PUBLIC DISCLOSURE

The IWF reports that the sample of Mr. KHARCHENKO, Viktor (RUS) has returned an Adverse Analytical Finding for Dehydrochlormethyltestosterone (S1.1 Anabolic Agents). As a consequence, the Athlete is provisionally suspended in view of a potential anti-doping rule violation. In any case where it is determined that the athlete did not commit an anti-doping rule violation, the relevant decision will also be published. The IWF will not make any further comments on the case until it is

IOC tackles the topic of nutritional supplements, their use and their effects

A Panel of leading medical and scientific experts concluded a three-day meeting at the International Olympic Committee (IOC) HQ to discuss the use of dietary supplements, their effects on athletes' health and performances and the risk of contamination and anti-doping issues. The IOC Medical and Scientific Commission has recognised the important role that sound nutrition practices play in protecting good health and promoting the optimum performance of athletes.  As part of its commitment to supporting the health and performance of athletes, it convened a meeting of experts in the field of dietary supplements to assess the evidence relating to the place of dietary supplements in the preparations of elite athletes. Particular focus was placed on their effects on athletes’ health and performances, and the risk of contamination with substances that may be harmful to health or that may trigger an adverse analytical finding, leading to an anti-doping rule violation. The use of dietary supplements is widespread among elite athletes, as it is among the general population. The expert group concluded, after three days of intensive discussions, that: Diet significantly influences athletic performance, but the use of supplements does not compensate for poor food choices and an inadequate diet. Supplementation with essential nutrients may be beneficial if a specific nutrient deficiency is medically diagnosed and a food-based solution cannot be easily implemented. A few supplements, from the many thousands of different products on the market, may provide performance or health-related benefits for some athletes in some types of sports, when optimum training, nutrition and recovery are already achieved. Quality assurance in supplement manufacture, storage and distribution is sometimes not strictly enforced, leading to products that are of poor quality or contaminated. Read the full conclusion from the expert group. Athletes contemplating the use of supplements and sports foods should consider their efficacy, their cost, the risk to health and performance, and the possibility that undeclared contaminants present in some supplements may cause an adverse analytical finding. The protection of athletes’ health and an awareness of the potential for harm must be paramount, and expert professional advice should be sought before embarking on supplement use. The consensus statement will be published in January 2018 (online in December 2017) in the British Journal of Sports Medicine and on www.olympic.org.

2017 WADA Annual Symposium: Play True „What do you play for?”

The World Anti-Doping Agency (WADA) held its Annual Symposium 13-15 March, in Lausanne hosting more than 500 anti-doping experts from NADOs, IFs, other ADOs, Laboratories, Media representatives and for the first time Governmental Representatives. The main theme of the Symposium was: „Tackling our Challenges and Strengthening the Future of Clean Sport”. The first day of the Symposium consisted of plenary sessions where Sir Craig Reedie, WADA President and Olivier Niggli, WADA Director General talked about how the Anti-Doping Community shall use the recent turbulent times as an opportunity to bring its fight against doping to a higher level. Among others, further speakers of the plenary sessions were Pavel Kolobkov, Sports Minister of the Russian Federation who gave an update on the recent Anti-Doping activities in Russia and Prof Richard McLaren who presented the investigation methods applied to deliver his Reports. On the second and third days of the Symposium the participants had the possibility to attend practical workshops on different topics such as: education, funding, testing programs, results management, risk assessment, good governance practises, stimulating cooperation between governments and sport, and ADOs and Laboratories, and anti-doping reporting mechanisms. On the occasion of one of the practical workshops the IWF was invited to present its system applicable to Sporting Bodies based on which the IWF Executive Board has the authority to impose sanctions on Member Federations violating the IWF Anti-Doping Rules. The rules were presented to the attendants of the workshop by Dr. Eva Nyirfa, IWF Legal Counsel. As always, the Symposium was a perfect opportunity for the IWF (represented by Dr. Patrick Schamasch, IWF Anti-Doping Commission Chairman, Dr. Zakia Bartagi, IWF ADC Member, Dr. Eva Nyirfa, Legal Counsel, Dr. Lilla Sagi, Junior Legal Counsel and Ms. Melody Exhenry, Administrative Assistant) to further strengthen its cooperation with other ADO’s. For more information related to the Symposium visit the following

WADA Suspends Accreditation of the Bogota Laboratory

The World Anti-Doping Agency (WADA) has suspended the accreditation of the Laboratorio de Control al Dopaje (the Bogota Laboratory) in Bogota, Colombia for a period of up to six months. The suspension is due to analytical issues, which led to a failure to comply with WADA’s External Quality Assessment Scheme (EQAS). The suspension, which took effect on 20 February 2017, prohibits the Bogota Laboratory from carrying out any anti-doping activities including all analyses of urine and blood samples, and is intended to provide an opportunity for the Laboratory to make concrete improvements to its operations and ensure future compliance. During the period of suspension, samples are required to be transported securely to another WADA-accredited laboratory, ensuring that athletes can have full confidence in continued high quality sample analysis and the wider anti-doping system. The decision to suspend the Bogota Laboratory is a direct result of the more stringent quality assessment procedures enacted by WADA to ensure that laboratories maintain the highest standards, and in turn, guarantee that the rights of clean athletes are protected. Pursuant to Article 13.7 of the World Anti-Doping Code (Code), the Bogota Laboratory may appeal this decision to the Court of Arbitration for Sport within 21 days of receipt of notice. During the period of suspension, the Bogota Laboratory shall address all non-conformities identified by the Laboratory Expert Group or WADA in any request for corrective action or otherwise, as well as any additional non-conformities identified through any WADA site visit during the suspension period. If the Bogota Laboratory satisfies the Disciplinary Committee in meeting these requirements, it may apply for reinstatement prior to the expiry of the six-month suspension period. Should the Laboratory not address the non-conformities by the end of the six-month suspension period, WADA may extend the suspension of the Laboratory’s accreditation for an additional period of up to six months. According to the International Standard for Laboratories (ISL), WADA is responsible for accrediting and re-accrediting anti-doping laboratories, thereby ensuring that they maintain the highest quality standards. This monitoring process is conducted in conjunction with International Organization for Standardization (ISO) assessment by independent national accreditation bodies that are full members of the International Laboratory Accreditation Cooperation (ILAC). Whenever a laboratory does not meet ISL requirements, WADA may suspend the laboratory’s accreditation (see Decision below). Decision of the Chairman of the WADA Executive Committee: As a result of the non-conformities identified by the LabEG and confirmed by the WADA Disciplinary Committee, the WADA accreditation of the Bogota Laboratory shall be suspended for a period of up to six months (or for such shorter or longer period as may be determined in accordance with paragraph 7 or paragraph 8, below). The suspension shall be effective immediately and shall be notified to all stakeholders by announcement on the WADA website, in accordance with ISL Art 4.4.14.3. All samples not yet analysed and all samples currently undergoing “A” or “B” confirmation procedures, and all samples where a presumptive analytical finding has been reported as of the date of this decision, shall be securely transported with a demonstrable chain of custody to another WADA-accredited laboratory as soon as possible and in any event no later than 14 calendar days following the date of this decision. The suspension period is intended to provide an opportunity for the Bogota Laboratory to focus all its efforts on concrete improvements to its operations with the objective of ensuring future compliance. A laboratory site visit and satisfactory analysis of EQAS samples shall also be conducted at the Bogota Laboratory's expense during the period of suspension, at a date to be determined by WADA, taking into account the time required by the Bogota Laboratory to address the non-conformities identified by the LabEG and confirmed by the WADA Disciplinary Committee. During the period of the suspension, the Bogota Laboratory shall address all of the said non-conformities, as well as any additional non-conformities identified by the LabEG or WADA in any request for corrective action or otherwise, including during the above WADA site visit. The LabEG should decide whether the Bogota Laboratory should be required to review any test results it previously reported and/or to reanalyse any samples. If the Laboratory completes all aspects of item 6 to WADA’s satisfaction prior to the expiry of the six month suspension period, it may apply to the Chair of the WADA Executive Committee for reinstatement of its WADA accreditation prior to the expiry of that period. In support of that application, the Laboratory shall provide documentation sufficient to demonstrate that all remedial and preventive actions required by WADA have been implemented in full, such that the Chair of the WADA Executive Committee can be confident in the accuracy and reliability of the doping control sample testing conducted by the Bogota Laboratory moving forward. Should any identified non-conformities not be resolved by the Bogota Laboratory by the end of the suspension period in a manner satisfactory to WADA, WADA may extend the suspension of the Laboratory’s WADA accreditation for an additional period of up to six months, in accordance with ISL Art 4.4.13.2.1.   Source:

Update on Reanalysis

The Disciplinary Commission of the International Olympic Committee has recently issued decisions in the reanalysis cases of the following athletes: Beijing 2008 CHEN, Xiexia (CHN) 48 kg CAO, Lei (CHN) 75 kg LIU, Chun Hong (CHN) 69 kg London 2012 SIMSEK, Sibel (TUR) 63 kg VARDANYAN, Norik (ARM) 94 kg ZAIROV, Intigam (AZE) 94 kg These athletes were found to have committed Anti-Doping Rule Violations and their results from the 2008/2012 Olympic Games were disqualified by the IOC DC. The IWF will take over the Results Managements of the above cases after the relevant appeal deadlines expire and the status of the cases will then be changed to 'closed IOC/ongoing IWF' on the IWF Reanalysis

PUBLIC DISCLOSURE

The IWF reports that the sample of Mr. ALKIKLI, Ali Miftah Saeid (LBA) has returned an Adverse Analytical Finding for Oxandrolone (S1.1. Anabolic Agents). As a consequence, the Athlete is provisionally suspended in view of a potential anti-doping rule violation. In any case where it is determined that the athlete did not commit an anti-doping rule violation, the relevant decision will also be published. The IWF will not make any further comments on the case until it is